Results 1 to 10 of about 4,630 (149)
Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat
Pharmaceuticals, 2018 The paper addresses the safety of febuxostat and summarizes reports on side effects and interactions of febuxostat published by the cut-off date (last day of literature search) of 20 March 2018.
Andreas Jordan
exaly +3 more sources
Benzbromarone as a Novel Candidate for Preventing Alzheimer's Disease: Evidence From Real‐World Data Screening and in Vitro Validation [PDF]
Clinical and Translational Science, Volume 19, Issue 7, July 2026.Drug repositioning analysis identifies candidate therapeutic agents for Alzheimer’s diseaseand supports further mechanistic and translational investigation. ABSTRACT Drug development for Alzheimer's disease (AD) remains challenging, with only a 0.4% success rate from Phase I trials to regulatory approval.
Sho Sakagami +11 more
wiley +2 more sources
Response to Allopurinol and Febuxostat According to the Fractional Excretion of Urate in Men With Gout [PDF]
Arthritis Care &Research, Volume 78, Issue 6, Page 781-787, June 2026.Objective Body mass index (BMI), glomerular filtration rate (GFR), and pretreatment urate levels have been reported to influence the urate‐lowering response to allopurinol. We investigated whether the fractional excretion of uric acid (FEUA) also modulates this response and relates to oxypurinol concentrations.
Pascal Richette +13 more
wiley +2 more sources
Evaluation of febuxostat in treating diabetic kidney disease with hyperuricemia: a systematic review and meta-analysis of randomized controlled trials [PDF]
Frontiers in MedicineBackgroundDiabetic kidney disease (DKD) combined with hyperuricemia (HUA) constitutes a pathological state of vicious cycle, where diabetic microvascular complications affect the kidneys and interact with persistent hyperuricemia.
Minghao Lin +7 more
doaj +2 more sources
Rheumatology and Therapy, 2023 Introduction This drug utilization study evaluated the impact of 2019 label changes on real-world febuxostat utilization among patients with gout. We describe the numbers and proportions of patients initiating febuxostat as new users (allopurinol-naïve ...
Alexandra Z. Sosinsky +4 more
doaj +1 more source
Saudi Journal of Kidney Diseases and Transplantation, 2023 Hyperuricemia is a risk factor for the progression of chronic kidney disease (CKD). We compared febuxostat versus allopurinol in the progression of CKD and hyperuricemia in 101 patients with Stage 3–4 CKD treated with febuxostat or allopurinol for at ...
Shankar Prasad Nagaraju +6 more
doaj +1 more source
A single-centre experience of febuxostat as a second-line urate-lowering therapy [PDF]
Malaysian Family Physician, 2021 Introduction: The purpose of this study was to describe the local experience in terms of drug efficacy and safety using a new xanthine oxidase inhibitor, febuxostat, as a second-line urate-lowering therapy (ULT) in gout patients with normal renal ...
Swee Gaik Ong, Hui Jen Ding
doaj +1 more source
Physiological Reports, 2021 We hypothesized acute moderate and drastic reductions in uric acid concentration exert different effects on arterial function in healthy normotensive and hypertensive adults.
Benjamin De Becker +9 more
doaj +1 more source
Febuxostat ameliorates secondary progressive experimental autoimmune encephalomyelitis by restoring mitochondrial energy production in a GOT2-dependent manner. [PDF]
PLoS ONE, 2017 Oxidative stress and mitochondrial dysfunction are important determinants of neurodegeneration in secondary progressive multiple sclerosis (SPMS). We previously showed that febuxostat, a xanthine oxidase inhibitor, ameliorated both relapsing-remitting ...
Josephe A Honorat +17 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Hyperuricemic nephropathy (HN) is a common clinical complication of hyperuricemia. The pathogenesis of HN is directly related to urea metabolism in the gut microbiota.
Zhen Xiong Zhao +8 more
doaj +1 more source